AstraZeneca (Lynparza and Selumetinib) is Buildings and Property in United Kingdom that focus on ribose polymerase business. They cover business area such as a portfolio, oncology drug, lynparza, ADP ribose polymerase (PARP) inhibitor, ovarian cancer, Selumetinib, an oral, potent, selective inhibitor, MEK, thyroid cancer.
-
Ribose Polymerase
-
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
England, United Kingdom
Private
a portfoliooncology druglynparzaADP ribose polymerase (PARP) inhibitorovarian cancerSelumetiniban oral, potent, selective inhibitorMEKthyroid cancer
* We use standard office opening hours in near AstraZeneca (Lynparza and Selumetinib)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AstraZeneca (Lynparza And Selumetinib) is Buildings and Property business from United Kingdom that founded in - ( years old in ), AstraZeneca (Lynparza and Selumetinib) business is focusing on Ribose Polymerase.
AstraZeneca (Lynparza and Selumetinib) headquarter office and corporate office address is located in 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA England, United Kingdom.
AstraZeneca (Lynparza and Selumetinib) was founded in United Kingdom.
In , AstraZeneca (Lynparza and Selumetinib) is currently focus on ribose polymerase sector.
Above is snippet of Google Trends for "ribose polymerase" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AstraZeneca (Lynparza and Selumetinib), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
